Kathryn Atkins, Author at Oncotarget

Oncotarget News

An Ancient Anti-cancer Mechanism: DISE

October 3, 2023

DISE is effective against all cancers we tested.” BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE,... read more

Oncotarget

Reassessing COVID-19 Precautions in 2023

September 27, 2023

The balance between appropriate precautions and the harm of social isolation always requires a thorough appraisal.”BUFFALO, NY- September 27, 2023 – A new editorial paper was published in Oncotarget's Volume... read more

Figure 4: Visual representation of the datasets used in this study on EC and PCOS

Oncotarget

Four Novel Receptors May Link Endometrial Cancer to PCOS

September 25, 2023

These findings hold significant promise for improving our understanding of mechanistic pathways leading to EC in PCOS.”BUFFALO, NY- September 25, 2023 – A new research paper was published in Oncotarget's... read more

Oncotarget

DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma

September 20, 2023

we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells.” BUFFALO, NY- September 20, 2023 – A new editorial paper... read more

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Oncotarget

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.”BUFFALO, NY- September 19, 2023 – A new research paper was... read more

Oncotarget

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

September 13, 2023

With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.”BUFFALO, NY- September 13, 2023 – A... read more

Oncotarget

Updates: MET Targeted Therapy for EXON 14 Mutations in Lung Cancer

September 11, 2023

The future looks bright for patients with MET mutations and NSCLC.”BUFFALO, NY- September 11, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023,... read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A... read more

Oncotarget

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new... read more

Figure 1: Glutamine metabolism effect in tumor microenvironment cells.

Oncotarget

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

August 16, 2023

These new findings evidence the necessity of more research in Gln metabolism to define the best therapeutic strategies for cancer patients.” BUFFALO, NY- August 16, 2023 – A new editorial... read more